報價延遲最少15分鐘:2026/02/28 16:49 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
279.15/-3.09
|
|
企業價值
189.56M
|
| 資產負債 |
|
每股賬面淨值
18.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.09M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. |
